KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Payables (2016 - 2025)

Merck (MRK) has disclosed Payables for 17 consecutive years, with $6.5 billion as the latest value for Q4 2025.

  • Quarterly Payables rose 6.18% to $6.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 billion through Dec 2025, up 6.18% year-over-year, with the annual reading at $6.5 billion for FY2025, 6.18% up from the prior year.
  • Payables for Q4 2025 was $6.5 billion at Merck, up from $6.2 billion in the prior quarter.
  • The five-year high for Payables was $6.5 billion in Q4 2025, with the low at $5.0 billion in Q3 2021.
  • Average Payables over 5 years is $5.7 billion, with a median of $5.6 billion recorded in 2023.
  • The sharpest move saw Payables decreased 5.56% in 2022, then increased 11.15% in 2025.
  • Over 5 years, Payables stood at $6.4 billion in 2021, then dropped by 3.59% to $6.1 billion in 2022, then fell by 3.92% to $5.9 billion in 2023, then increased by 4.33% to $6.2 billion in 2024, then increased by 6.18% to $6.5 billion in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $6.5 billion, $6.2 billion, and $5.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.